Betta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lieming Ding

Chief Executive Officer (CEO)

CN¥3.0m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	10.8yrs
Participación del CEO	0.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

CEO

Lieming Ding (61 yo)

10.8yrs

Permanencia

CN¥2,955,800

Compensación

Dr. Lieming Ding founded Betta Pharmaceuticals Co., Ltd.(also known as Zhejiang BetaPharma Co., Ltd) in 2002 and serves as its Chairman. Dr. Ding has been Chief Executive Officer and General Manager of Bet...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lieming Ding	Founder	no data	CN¥2.96m	0.24% CN¥ 36.4m
Jianxun Fan	VP, CFO & Director	no data	CN¥1.36m	0.031% CN¥ 4.8m
Jiang Wan	Senior VP	4.6yrs	CN¥2.56m	0.025% CN¥ 3.9m
Jiabing Wang	Senior VP	4.6yrs	CN¥2.58m	0.047% CN¥ 7.3m
Jia Tong	Director	no data	CN¥1.35m	0.039% CN¥ 6.1m
Wei Wang	Independent Director	4.6yrs	CN¥120.00k	sin datos
Cai Jiangnan	Independent Director	4.6yrs	CN¥120.00k	sin datos
Yangnan Zhang	Chairman of the Supervisory Board & Senior Director of Project Declaration	4.6yrs	sin datos	sin datos
Zhihua Yu	Director	4.6yrs	sin datos	sin datos
Tian Xu	Director	1.7yrs	sin datos	sin datos
Fei Wu	Supervisor	no data	sin datos	sin datos
Jiajia Xiao	Independent Director	1.7yrs	CN¥25.10k	sin datos

4.6yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300558 se considera experimentada (4.4 años de antigüedad promedio).

Betta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Recent updates

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80

Analysts update estimates

Third-quarter earnings released: Revenue and earnings beat expectations

Third quarter earnings released

New 90-day low: CN¥108

Analysts update estimates

New 90-day low - CN¥110

Ningbo Kaiming Innovation Technology Co., Ltd. completed the acquisition of Zhejiang Betta Pharmaceutical Technology Co., Ltd. from Betta Pharmaceuticals Co., Ltd. (SZSE:300558).

Earnings released

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 06, 2020

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 1.002 billion in funding

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media